Biophytis rebounds by almost 7% on the Paris Bourse on Friday, following the presentation of its Phase 3 protocol for the treatment of sarcopenia.

According to the information unveiled at the International Conference on Frailty & Sarcopenia (ICFSR), currently being held in Albuquerque, the study is expected to include 932 subjects.

The trial aims to demonstrate the potential of Ruvembri, the company's lead candidate, in the treatment of sarcopenic patients at risk of functional decline and disability.

Despite today's rebound, Biophytis shares are still down over 16% for the week as a whole, a decline that professionals attribute to the prospect of a forthcoming capital increase.

'On Monday, Biophytis sent out the invitations and agenda for the forthcoming AGM to be held on April 2. It appears that most of the resolutions concern financing, mainly via a capital increase", point out Invest Securities' analysts.

In a press release published this morning, CEO Stanislas Veillet acknowledges that the company is "actively" seeking pharmaceutical partners to develop Ruvembri and finance its access to the market.

Copyright (c) 2024 CercleFinance.com. All rights reserved.